I saw that on a 'Pharmaceutical Technology' site, but in retrospect they might just be blending the weight loss trials with a sleep apnea one to get you to buy their report :
Tirzepatide is under clinical development by Eli Lilly and Co and currently in Phase III for Obstructive Sleep Apnea. According to GlobalData, Phase III drugs for Obstructive Sleep Apnea have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tirzepatide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Ann: ResMed Announces Results for the Fourth Quarter of FY2023, page-194
-
- There are more pages in this discussion • 178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$35.92 |
Change
0.320(0.90%) |
Mkt cap ! $22.02B | |||
| Open | High | Low | Value | Volume |
| $35.67 | $35.98 | $35.67 | $17.70M | 493.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $35.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $35.97 | 9003 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| RMD (ASX) Chart |